Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets

Pathogen-reduced (PR) platelets are routinely used in many countries. Some studies reported changes in platelet and red blood cell (RBC) transfusion requirements in patients who received PR platelets when compared to conventional (CONV) platelets. Over a 28-month period we retrospectively analysed platelet utilisation, RBC transfusion trends, and transfusion reaction rates data from all transfused adult patients transfused at the Yale-New Haven Hospital, New Haven, CT, USA. We determined the number of RBC and platelet components administered between 2 and 24, 48, 72 or 96 h. A total of 3767 patients received 21 907 platelet components (CONV = 8912; PR = 12 995); 1,087 patients received only CONV platelets (1578 components) and 1,466 patients received only PR platelets (2604 components). The number of subsequently transfused platelet components was slightly higher following PR platelet components (P < 0 center dot 05); however, fewer RBCs were transfused following PR platelet administration (P < 0 center dot 05). The mean time-to-next platelet component transfusion was slightly shorter following PR platelet transfusion (P = 0 center dot 002). The rate of non-septic transfusion reactions did not differ (all P > 0 center dot 05). Septic transfusion reactions (N = 5) were seen only after CONV platelet transfusions (P = 0 center dot 011). These results provide evidence for comparable clinical efficacy of PR and CONV platelets. PR platelets eliminated septic transfusion reactions without increased risk of other types of transfusions with only slight increase in platelet utilisation.